Get the Stockscreener App
9.60
1.69%
0.16
After Hours:
9.26
-0.34
-3.54%
Relay Therapeutics Inc stock is traded at $9.60, with a volume of 1.50M.
It is up +1.69% in the last 24 hours and up +4.12% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$9.44
Open:
$9.54
24h Volume:
1.50M
Relative Volume:
0.63
Market Cap:
$1.72B
Revenue:
$15.36M
Net Income/Loss:
$-276.48M
P/E Ratio:
-5.952
EPS:
-1.6129
Net Cash Flow:
$-235.87M
1W Performance:
-3.32%
1M Performance:
+4.12%
6M Performance:
+119.18%
1Y Performance:
+224.32%
1-Day Range:
$9.54
$9.95
1-Week Range:
$9.265
$10.75
52-Week Range:
$1.775
$11.49
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
9.60 | 1.69B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies - Traders Union
Aug Summary: Will Relay Therapeutics Inc benefit from government policy2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook for RLAY Q1 Earnings - MarketBeat
RLAY: HC Wainwright & Co. Raises Price Target to $19.00, Maintai - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target on trial data - Investing.com
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy? - Sahm
Aug Update: What is the earnings history of Relay Therapeutics IncTrade Analysis Report & Target Return Focused Picks - baoquankhu1.vn
Relay Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - AOL.com
Raymond James reiterates Strong Buy on Relay Therapeutics stock By Investing.com - Investing.com Canada
Profit Review: Can Relay Therapeutics Inc sustain its profitability2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Assessing Relay Therapeutics (RLAY) Valuation After New Zovegalisib Breast Cancer Data And Ongoing Phase 3 Trial - Sahm
Relay Therapeutics Price Target Raised to $17.00 - National Today
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Wells Fargo Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Oppenheimer reiterates Relay Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Relay Therapeutics (RLAY) Unveils Promising Phase 1/2 Trial Resu - GuruFocus
Relay Therapeutics Reports Promising Phase 3 Data for Zovegalisib + Fulvestrant in PI3Kα-Mutated HR+/HER2- Metastatic Breast Cancer at ESMO TAT 2026 12 - Minichart
Relay Therapeutics Sees Unusually Large Options Volume - National Today
Relay Therapeutics Sees Unusually Large Options Volume (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free SurvivalWhat Does This Means For Pretreated Breast Cancer Patients? - Benzinga
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - Bitget
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data - TipRanks
Relay Therapeutics Announces Data from Zovegalisib Plus Fulvestrant At the Phase 3 Dose of 400Mg BID Fed - marketscreener.com
Relay Therapeutics reports 11.1-month median PFS for zovegalisib 400mg BID fed in PI3Kα-mutant MBC - TradingView
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Relay Therapeutics moves ReDiscover regimen with zovegalisib and fulvestrant to Phase 3 trial - Traders Union
Experimental Relay cancer drug combo shows 11.1-month progression-free survival - Stock Titan
Relay Therapeutics reports phase 3 trial data for breast cancer drug - Investing.com
Commodore Capital Boosts Stake in Relay Therapeutics - National Today
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors? - simplywall.st
Commodore Capital LP Raises Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY) - The Globe and Mail
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY) - The Globe and Mail
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):